Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated prediagnostic blood samples

Florentin Späth, Carl Wibom, Esmeralda J.M. Krop, Antonio Izarra Santamaria, Ann-Sofie Johansson, Ingvar A. Bergdahl, Johan Hultdin, Roel Vermeulen, and Beatrice Melin

Disclosures: This work was supported by the Swedish Research Council (BM), Swedish Cancer foundation (BM), Northern Sweden Cancer foundation (FS, CW, BM), and the Umea University Hospital cutting edge grant (BM). All authors declare no competing financial interests in relation to this or outside this work.

Contributions: FS, AJ, IB, RV, and BM were involved in the conception and the design of the study. EK and RV supervised immune marker analyses. FS, CW, EK, RV, and BM developed methods. JH interpreted M-protein assessment. FS and AI acquired and interpreted clinical data. FS and CW performed data analyses. FS, CW, AI, RV, and BM interpreted the data. FS and CW wrote the paper with input from all authors. All authors reviewed and approved the final version of the manuscript. RV and BM supervised the study.